As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
16 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:
16 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 600 600 |
45%
45%
|
|
| Gross Profit | 584 584 |
44%
44%
|
|
| EBITDA | 77 77 |
297%
297%
|
|
| EBIT (Operating Income) EBIT | 76 76 |
287%
287%
|
|
| Net Profit | -8.78 -8.78 |
93%
93%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
| Head office | United States |
| CEO | Jon Stonehouse |
| Employees | 580 |
| Founded | 1986 |
| Website | www.biocryst.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


